{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:47:09Z","timestamp":1775044029247,"version":"3.50.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical Research Futures Fund - Australian Federal Government","award":["1152285"],"award-info":[{"award-number":["1152285"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>This study compares aspirin to enoxaparin for symptomatic VTE prophylaxis within 90 days of any type of hip or knee arthroplasty performed for any diagnosis, in patients enrolled in the CRISTAL trial.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>CRISTAL was a cluster-randomised crossover, registry-nested non-inferiority trial across 31 hospitals in Australia. The primary publication was restricted to patients undergoing primary total hip or knee arthroplasty for a diagnosis of osteoarthritis. This report includes all enrolled patients undergoing hip or knee arthroplasty procedures (partial or total, primary or revision) performed for any indication. Hospitals were randomized to administer patients aspirin (100mg daily) or enoxaparin (40mg daily), for 35 days after hip arthroplasty and 14 days after knee arthroplasty. Crossover occurred after the patient enrolment target had been met for the first group. The primary outcome was symptomatic VTE within 90 days. Analyses were performed by randomization group.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Between April 20, 2019 and December 18, 2020, 12384 patients were enrolled (7238 aspirin group and 5146 enoxaparin). Of these, 6901 (95.3%) given aspirin and 4827 (93.8%) given enoxaparin (total 11728, 94.7%) were included in the final analyses. Within 90 days, symptomatic VTE occurred in 226 (3.27%) aspirin patients and 85 (1.76%) enoxaparin patients, significant for the superiority of enoxaparin (estimated treatment difference 1.85%, 95% CI 0.59% to 3.10%, p = 0.004). Joint-related reoperation within 90 days was lower in the enoxaparin group (109\/4827 (2.26%) vs 171\/6896 (2.47%) with aspirin, estimated difference 0.77%; 95% CI 0.06% to 1.47%, p = 0.03). There were no significant differences in the other secondary outcomes.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In patients undergoing hip or knee arthroplasty (of any type, performed for any indication) enrolled in the CRISTAL trial, aspirin compared to enoxaparin resulted in a significantly higher rate of symptomatic VTE and joint-related reoperation within 90 days. These findings extend the applicability of the CRISTAL trial results.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>Anzctr.org.au, identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=ACTRN12618001879257\" xlink:type=\"simple\">ACTRN12618001879257<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0298152","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T18:23:47Z","timestamp":1713291827000},"page":"e0298152","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Aspirin or enoxaparin for VTE prophylaxis after primary partial, total or revision hip or knee arthroplasty: A secondary analysis from the CRISTAL cluster randomized trial"],"prefix":"10.1371","volume":"19","author":[{"name":"The CRISTAL Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"issue":"8","key":"pone.0298152.ref001","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1712746","article-title":"Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty","volume":"378","author":"DR Anderson","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0298152.ref002","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-159-7-201310010-00018","article-title":"Aspirin versus low-molecular-weight heparin after total hip arthroplasty","volume":"159","author":"DR Anderson","year":"2013","journal-title":"Ann Intern Med"},{"issue":"8","key":"pone.0298152.ref003","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jama.2022.13416","article-title":"Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial","volume":"328","author":"CRISTAL","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"pone.0298152.ref004","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12891-019-2409-3","article-title":"Comparing Australian orthopaedic surgeons\u2019 reported use of thromboprophylaxis following arthroplasty in 2012 and 2017","volume":"20","author":"C Mirkazemi","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"issue":"Suppl 1","key":"pone.0298152.ref005","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2106\/JBJS.21.01529","article-title":"Recommendations from the ICM-VTE: Hip & Knee","volume":"104","author":"I-V Hip","year":"2022","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"pone.0298152.ref006","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s13063-021-05486-0","article-title":"CRISTAL (a cluster-randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study): statistical analysis plan","volume":"22","author":"VS Sidhu","year":"2021","journal-title":"Trials"},{"issue":"11","key":"pone.0298152.ref007","doi-asserted-by":"crossref","first-page":"e031657","DOI":"10.1136\/bmjopen-2019-031657","article-title":"CRISTAL: protocol for a cluster randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study","volume":"9","author":"VS Sidhu","year":"2019","journal-title":"BMJ Open"},{"key":"pone.0298152.ref008","article-title":"Comparison of 90-day adverse events associated with aspirin and potent anticoagulation use for venous thromboembolism prophylaxis: A cohort study of 72,288 total knee and 35,142 total hip arthroplasty patients","author":"G Singh","year":"2023","journal-title":"J Arthroplasty"},{"key":"pone.0298152.ref009","article-title":"Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty","author":"AS Piple","year":"2023","journal-title":"J Arthroplasty"},{"issue":"3","key":"pone.0298152.ref010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2205973","article-title":"Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture","volume":"388","author":"C Major Extremity Trauma Research","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0298152.ref011","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.arth.2015.07.001","article-title":"Administration of Aspirin as a Prophylaxis Agent Against Venous Thromboembolism Results in Lower Incidence of Periprosthetic Joint Infection","volume":"30","author":"R Huang","year":"2015","journal-title":"J Arthroplasty"},{"issue":"12","key":"pone.0298152.ref012","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1016\/j.arth.2020.07.004","article-title":"Persistent Wound Drainage among Total Joint Arthroplasty Patients Receiving Aspirin vs Coumadin","volume":"35","author":"V Singh","year":"2020","journal-title":"J Arthroplasty"},{"issue":"5","key":"pone.0298152.ref013","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.arth.2022.01.008","article-title":"Aspirin Administered for Venous Thromboembolism Prophylaxis May Protect Against Stiffness Following Total Knee Arthroplasty","volume":"37","author":"N Shohat","year":"2022","journal-title":"J Arthroplasty"},{"issue":"7","key":"pone.0298152.ref014","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2106\/JBJS.18.00335","article-title":"Potent Anticoagulation Does Not Reduce Venous Thromboembolism in High-Risk Patients","volume":"101","author":"TL Tan","year":"2019","journal-title":"J Bone Joint Surg Am"},{"issue":"9","key":"pone.0298152.ref015","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s11999-017-5394-6","article-title":"Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?","volume":"475","author":"A Bala","year":"2017","journal-title":"Clin Orthop Relat Res"},{"issue":"9","key":"pone.0298152.ref016","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.arth.2016.02.074","article-title":"Aspirin Is as Effective as and Safer Than Warfarin for Patients at Higher Risk of Venous Thromboembolism Undergoing Total Joint Arthroplasty","volume":"31","author":"RC Huang","year":"2016","journal-title":"J Arthroplasty"},{"issue":"7","key":"pone.0298152.ref017","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.arth.2015.12.042","article-title":"Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis","volume":"31","author":"S Heller","year":"2016","journal-title":"J Arthroplasty"},{"issue":"10","key":"pone.0298152.ref018","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.arth.2016.03.031","article-title":"Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty","volume":"31","author":"GK Deirmengian","year":"2016","journal-title":"J Arthroplasty"},{"issue":"1","key":"pone.0298152.ref019","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1302\/0301-620X.96B1.31569","article-title":"Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement","volume":"96","author":"BV Bloch","year":"2014","journal-title":"Bone Joint J"},{"issue":"1","key":"pone.0298152.ref020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11999-012-2488-z","article-title":"Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty","volume":"471","author":"BP Gillette","year":"2013","journal-title":"Clin Orthop Relat Res"},{"issue":"10","key":"pone.0298152.ref021","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00264-012-1588-4","article-title":"Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol","volume":"36","author":"E Vulcano","year":"2012","journal-title":"Int Orthop"},{"issue":"7","key":"pone.0298152.ref022","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.arth.2009.06.021","article-title":"Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients?","volume":"25","author":"KJ Bozic","year":"2010","journal-title":"J Arthroplasty"},{"issue":"7","key":"pone.0298152.ref023","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1302\/0301-620X.94B7.29129","article-title":"The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using National Joint Registry Data","volume":"94","author":"SS Jameson","year":"2012","journal-title":"J Bone Joint Surg Br"},{"issue":"11","key":"pone.0298152.ref024","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1302\/0301-620X.93B11.27622","article-title":"The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry","volume":"93","author":"SS Jameson","year":"2011","journal-title":"J Bone Joint Surg Br"},{"issue":"2","key":"pone.0298152.ref025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.arth.2011.04.006","article-title":"Pulmonary embolism prophylaxis in more than 30,000 total knee arthroplasty patients: is there a best choice?","volume":"27","author":"M Khatod","year":"2012","journal-title":"J Arthroplasty"},{"issue":"11","key":"pone.0298152.ref026","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1016\/j.arth.2017.05.042","article-title":"Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty","volume":"32","author":"G Cafri","year":"2017","journal-title":"J Arthroplasty"},{"issue":"1","key":"pone.0298152.ref027","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamasurg.2018.3858","article-title":"Association of Aspirin With Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Compared With Other Anticoagulants: A Noninferiority Analysis","volume":"154","author":"BR Hood","year":"2019","journal-title":"JAMA Surg"},{"issue":"3","key":"pone.0298152.ref028","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamainternmed.2019.6108","article-title":"Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials","volume":"180","author":"GS Matharu","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"6","key":"pone.0298152.ref029","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2106\/JBJS.18.00143","article-title":"The Use of Aspirin for Prophylaxis Against Venous Thromboembolism Decreases Mortality Following Primary Total Joint Arthroplasty","volume":"101","author":"AJ Rondon","year":"2019","journal-title":"J Bone Joint Surg Am"},{"issue":"6","key":"pone.0298152.ref030","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.arth.2021.01.025","article-title":"Non-Inferiority of Aspirin for Venous Thromboembolism Prophylaxis After Hip Arthroplasty in a Statewide Registry","volume":"36","author":"SR Muscatelli","year":"2021","journal-title":"J Arthroplasty"},{"key":"pone.0298152.ref031","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/BLO.0b013e318156c13f","article-title":"Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol","volume":"463","author":"B Beksac","year":"2007","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"pone.0298152.ref032","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1302\/0301-620X.90B5.19744","article-title":"Multimodal thromboprophylaxis following primary hip arthroplasty: the role of adjuvant intermittent pneumatic calf compression","volume":"90","author":"J Daniel","year":"2008","journal-title":"J Bone Joint Surg Br"},{"issue":"12","key":"pone.0298152.ref033","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.2106\/JBJS.F.00235","article-title":"Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment","volume":"89","author":"LD Dorr","year":"2007","journal-title":"J Bone Joint Surg Am"},{"issue":"3","key":"pone.0298152.ref034","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.arth.2014.10.018","article-title":"Mobile compression devices and aspirin for VTE prophylaxis following simultaneous bilateral total knee arthroplasty","volume":"30","author":"D Nam","year":"2015","journal-title":"J Arthroplasty"},{"issue":"5","key":"pone.0298152.ref035","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1302\/0301-620X.98B5.34996","article-title":"Fatal pulmonary embolism following elective total hip arthroplasty: a 12-year study","volume":"98","author":"E Bayley","year":"2016","journal-title":"Bone Joint J"},{"issue":"11","key":"pone.0298152.ref036","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.arth.2015.10.023","article-title":"Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin","volume":"31","author":"KN Radzak","year":"2016","journal-title":"J Arthroplasty"},{"issue":"1","key":"pone.0298152.ref037","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4055\/cios.2017.9.1.37","article-title":"Intermittent Pneumatic Compression for the Prevention of Venous Thromboembolism after Total Hip Arthroplasty","volume":"9","author":"HS Kwak","year":"2017","journal-title":"Clin Orthop Surg"},{"issue":"7496","key":"pone.0298152.ref038","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/bmj.330.7496.895","article-title":"Reader\u2019s guide to critical appraisal of cohort studies: 1. Role and design","volume":"330","author":"PA Rochon","year":"2005","journal-title":"BMJ"},{"issue":"1","key":"pone.0298152.ref039","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/jor.23711","article-title":"Trends in hip replacements between 1999 and 2012 in Sweden","volume":"36","author":"P Cnudde","year":"2018","journal-title":"J Orthop Res"},{"issue":"1\u20132","key":"pone.0298152.ref040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ans.15529","article-title":"Declining early mortality after hip and knee arthroplasty","volume":"90","author":"IA Harris","year":"2020","journal-title":"ANZ J Surg"},{"issue":"2","key":"pone.0298152.ref041","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.38232","article-title":"Changes in mortality patterns following total hip or knee arthroplasty over the past two decades: a nationwide cohort study","volume":"66","author":"A Lalmohamed","year":"2014","journal-title":"Arthritis Rheumatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T18:24:14Z","timestamp":1713291854000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298152"}},"subtitle":[],"editor":[{"given":"Yoshihiro","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0298152","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]}}}